Replicating single-cycle adenovirus vectors generate amplified influenza vaccine responses

Journal of Virology

Volumn 91, Issue 2, 2017, Pages

  Crosby, Catherine M ^a,b,d   Matchett, William E ^b   Anguiano Zarate, Stephanie S ^a   Parks, Christopher A ^a   Weaver, Eric A ^a,e   Pease, Larry R ^b   Webby, Richard J ^a   Barry, Michael A ^a,b,c  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^e UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Adenovirus; Gene based vaccine; Replication defective; Single cycle

Indexed keywords

ADENOVIRUS VECTOR; INFLUENZA VACCINE; PROTEIN ANTIBODY; VIRUS HEMAGGLUTININ; COMPLEMENTARY DNA; HYBRID PROTEIN; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADENOVIRIDAE; ADENOVIRUS SEROTYPE 6; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG POTENCY; FEMALE; GENE EXPRESSION; GENE REPLICATION; HA GENE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLUENZA A; INFLUENZA A VIRUS (A/PUERTO RICO/8/1934(H1N1)); MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; RHESUS MONKEY; SYRIAN HAMSTER; ANIMAL; CELL LINE; DISEASE MODEL; DNA REPLICATION; GENE VECTOR; GENETICS; HAMSTER; IMMUNIZATION; IMMUNOLOGY; INFLUENZA A VIRUS; INTRANASAL DRUG ADMINISTRATION; ORTHOMYXOVIRIDAE INFECTIONS; SIGMODONTINAE; VIRUS REPLICATION;

ADENOVIRIDAE; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CELL LINE; CRICETINAE; DISEASE MODELS, ANIMAL; DNA REPLICATION; DNA, COMPLEMENTARY; FEMALE; GENE EXPRESSION; GENETIC VECTORS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNIZATION; INFLUENZA A VIRUS; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE INFECTIONS; RATS; RECOMBINANT FUSION PROTEINS; SIGMODONTINAE; VIRUS REPLICATION;

EID: 85008690094     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00720-16     Document Type: Article

References (49)

1. CDC. 2004. Update: influenza activity-United States and worldwide, 2003-04 season, and composition of the 2004-05 influenza vaccine. MMWR Morb Mortal Wkly Rep 53:547-552.
2. CDC. 2012. Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep 61:613-618.
3. Flannery B, Clippard J, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Petrie JG, McLean HQ, Belongia EA, Gaglani M, Berman L, Foust A, Sessions W, Thaker SN, Spencer S, Fry AM, Centers for Disease Control and Prevention. 2015. Early estimates of seasonal influenza vaccine effectiveness-United States, January 2015. MMWR Morb Mortal Wkly Rep 64:10-15.
4. Clements ML, Murphy BR. 1986. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol 23:66-72.
5. Liew FY, Russell SM, Appleyard G, Brand CM, Beale J. 1984. Crossprotection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity. Eur J Immunol 14:350-356. https://doi.org/10.1002/eji.1830140414.
6. Webby RJ, Webster RG. 2003. Are we ready for pandemic influenza? Science 302:1519-1522. https://doi.org/10.1126/science.1090350.
7. Doherty PC, Turner SJ, Webby RG, Thomas PG. 2006. Influenza and the challenge for immunology. Nat Immunol 7:449-455.
8. Webby RJ, Woolcock PR, Krauss SL, Walker DB, Chin PS, Shortridge KF, Webster RG. 2003. Multiple genotypes of nonpathogenic H6N2 influenza viruses isolated from chickens in California. Avian Dis 47:905-910. https://doi.org/10.1637/0005-2086-47.s3.905.
9. Osterholm MT, Kelley NS, Sommer A, Belongia EA. 2012. Efficacy and effectiveness of influenza vaccines: a systematic review and metaanalysis. Lancet Infect Dis 12:36-44. https://doi.org/10.1016/S1473-3099(11)70295-X.
10. Subbramanian RA, Basha S, Shata MT, Brady RC, Bernstein DI. 2010. Pandemic and seasonal H1N1 influenza hemagglutinin-specific T cell responses elicited by seasonal influenza vaccination. Vaccine 28: 8258-8267. https://doi.org/10.1016/j.vaccine.2010.10.077.
11. WHO. 2014. Influenza fact sheet. WHO, Geneva, Switzerland.
12. WHO. 2004. Influenza pandemic preparedness and response. Executive board 115th session agenda item 4.17, Geneva Switzerland, 11-12 November 2004. WHO, Geneva, Switzerland.
13. WHO. 2004. Vaccines for pandemic influenza: informal meeting of WHO, influenza vaccine manufactures, national licensing agencies, and government representatives on influenza pandemic vaccines, Geneva, Switzerland, 11-12 November 2004. WHO, Geneva, Switzerland.
14. Lanthier PA, Huston GE, Moquin A, Eaton SM. 2011. Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses. Vaccine 29:7849-7856. https://doi.org/10.1016/j.vaccine.2011.07.093.
15. Basha S, Hazenfeld S, Brady RC, Subbramanian RA. 2011. Comparison of antibody and T-cell responses elicited by licensed inactivated-and live-attenuated influenza vaccines against H3N2 hemagglutinin. Hum Immunol 72:463-469. https://doi.org/10.1016/j.humimm.2011.03.001.
16. McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, Ewen C, Kane KP, Bleackley RC. 2006. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 176:6333-6339. https://doi.org/10.4049/jimmunol.176.10.6333.
17. CDC. 1999. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 48:1-28.
18. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A. 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745-1749. https://doi.org/10.1126/science.8456302.
19. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. 1993 DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A 90:11478-11482. https://doi.org/10.1073/pnas.90.24.11478.
20. Ulmer JB, Donnelly JJ, Liu MA. 1994. Presentation of an exogenous antigen by major histocompatibility complex class I molecules. Eur J Immunol 24:1590-1596. https://doi.org/10.1002/eji.1830240721.
21. Shiver JW, Fu T-M, Chen L, Casimiro DR, Davies M-E, Evans RK, Zhang Z-Q, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, Emini EA. 2002. Replication-incompetent adenoviral vaccine vector elicits effective antiimmunodeficiency-virus immunity. Nature 415:331-335. https://doi.org/10.1038/415331a.
22. Maeda K, West K, Hayasaka D, Ennis FA, Terajima M. 2005. Recombinant adenovirus vector vaccine induces stronger cytotoxic T-cell responses than recombinant vaccinia virus vector, plasmid DNA, or a combination of these. Viral Immunol 18:657-667. https://doi.org/10.1089/vim.2005.18.657.
23. He B, Zheng B-J, Wang Q, Du L, Jiang S, Lu L. 2015. Adenovirus-based vaccines against avian-origin H5N1 influenza viruses. Microbes Infect 17:135-141. https://doi.org/10.1016/j.micinf.2014.11.003.
24. Hsu KH, Lubeck MD, Bhat BM, Bhat RA, Kostek B, Selling BH, Mizutani S, Davis AR, Hung PP. 1994. Efficacy of adenovirus-vectored respiratory syncytial virus vaccines in a new ferret model. Vaccine 12:607-612. https://doi.org/10.1016/0264-410X(94)90264-X.
25. Berkner KL. 1988. Development of adenovirus vectors for the expression of heterologous genes. Biotechniques 6:616-629.
26. Benihoud K, Yeh P, Perricaudet M. 1999. Adenovirus vectors for gene delivery. Curr Opin Biotechnol 10:440-447. https://doi.org/10.1016/S0958-1669(99)00007-5.
27. Santosuosso M, McCormick S, Xing Z. 2005. Adenoviral vectors for mucosal vaccination against infectious diseases. Viral Immunol 18: 283-291. https://doi.org/10.1089/vim.2005.18.283.
28. Auguste AJ, Kaelber JT, Fokam EB, Guzman H, Carrington CV, Erasmus JH, Kamgang B, Popov VL, Jakana J, Liu X, Wood TG, Widen SG, Vasilakis N, Tesh RB, Chiu W, Weaver SC. 2015. A newly isolated reovirus has the simplest genomic and structural organization of any reovirus. J Virol 89:676-687. https://doi.org/10.1128/JVI.02264-14.
29. Scallan CD, Tingley DW, Lindbloom JD, Toomey JS, Tucker SN. 2013. An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin Vaccine Immunol 20:85-94. https://doi.org/10.1128/CVI.00552-12.
30. Weaver EA, Barry MA. 2013. Low seroprevalent species D adenovirus vectors as influenza vaccines. PLoS One 8:e73313. https://doi.org/10.1371/journal.pone.0073313.
31. Weaver EA. 2014. Vaccines within vaccines: the use of adenovirus types 4 and 7 as influenza vaccine vectors. Hum Vaccin Immunother 10: 544-556. https://doi.org/10.4161/hv.27238.
32. Tutykhina IL, Logunov DY, Shcherbinin DN, Shmarov MM, Tukhvatulin AI, Naroditsky BS, Gintsburg AL. 2011. Development of adenoviral vectorbased mucosal vaccine against influenza. J Mol Med 89:331-341. https://doi.org/10.1007/s00109-010-0696-0.
33. Toro H, Tang DC, Suarez DL, Zhang J, Shi Z. 2008. Protection of chickens against avian influenza with non-replicating adenovirusvectored vaccine. Vaccine 26:2640-2646. https://doi.org/10.1016/j.vaccine.2008.02.056.
34. Weaver EA, Rubrum AM, Webby RJ, Barry MA. 2011. Protection against divergent influenza H1N1 virus by a centralized influenza hemagglutinin. PLoS One 6:e18314. https://doi.org/10.1371/journal.pone.0018314.
35. Barouch DH, Korber B. 2010. HIV-1 vaccine development after STEP. Annu Rev Med 61:153-167. https://doi.org/10.1146/annurev.med.042508.093728.
36. Gray G, Buchbinder S, Duerr A. 2010. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 5:357-361. https://doi.org/10.1097/COH.0b013e32833d2d2b.
37. Alexander J, Gurwith M, Mendy J, Vang L, Manayani D, Avanzini J, Guenther B, Farness P, Haynes BF, Liao H, Montefiori DC, LaBranche CC, Mayall T. 2012. Development of a HIV-1 vaccine using an orallyadministered, replication-competent adenovirus serotype 4 vector expressing Env clade C glycoprotein. Retrovirology 9(Suppl 2):P35 https://doi.org/10.1186/1742-4690-9-S2-P35.
38. Gurwith M, Lock M, Taylor EM, Ishioka G, Alexander J, Mayall T, Ervin JE, Greenberg RN, Strout C, Treanor JJ, Webby R, Wright PF. 2013. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebocontrolled, phase 1 study. Lancet Infect Dis 13:238-250. https://doi.org/10.1016/S1473-3099(12)70345-6.
39. Crosby CM, Barry MA. 2014. IIIa deleted adenovirus as a single-cycle genome replicating vector. Virology 462-463:158-165.
40. Crosby CM, Nehete P, Sastry KJ, Barry MA. 2015. Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines. J Virol 89:669-675. https://doi.org/10.1128/JVI.02184-14.
41. Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K, Wold WS. 2006. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 66:1270-1276. https://doi.org/10.1158/0008-5472.CAN-05-3497.
42. Thomas MA, Spencer JF, Wold WS. 2007. Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors. Methods Mol Med 130: 169-183.
43. Potter CW, Oxford JS. 1979. Determinants of immunity to influenza infection in man. Br Med Bull 35:69-75.
44. Eichelberger MC. 2007. The cotton rat as a model to study influenza pathogenesis and immunity. Viral Immunol 20:243-249. https://doi.org/10.1089/vim.2007.0017.
45. Steel JC, Morrison BJ, Mannan P, Abu-Asab MS, Wildner O, Miles BK, Yim KC, Ramanan V, Prince GA, Morris JC. 2007. Immunocompetent syngeneic cotton rat tumor models for the assessment of replicationcompetent oncolytic adenovirus. Virology 369:131-142. https://doi.org/10.1016/j.virol.2007.07.022.
46. Van Kampen KR, Shi Z, Gao P, Zhang J, Foster KW, Chen DT, Marks D, Elmets CA, Tang DC. 2005. Safety and immunogenicity of adenovirusvectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23:1029-1036. https://doi.org/10.1016/j.vaccine.2004.07.043.
47. Peng B, Wang LR, Gomez-Roman VR, Davis-Warren A, Montefiori DC, Kalyanaraman VS, Venzon D, Zhao J, Kan E, Rowell TJ, Murthy KK, Srivastava I, Barnett SW, Robert-Guroff M. 2005. Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies. J Virol 79:10200-10209. https://doi.org/10.1128/JVI.79.16.10200-10209.2005.
48. Weaver EA, Nehete PN, Buchl SS, Senac JS, Palmer D, Ng P, Sastry KJ, Barry MA. 2009. Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines. PLoS One 4:e5059. https://doi.org/10.1371/journal.pone.0005059.
49. Ying B, Toth K, Spencer JF, Meyer J, Tollefson AE, Patra D, Dhar D, Shashkova EV, Kuppuswamy M, Doronin K, Thomas MA, Zumstein LA, Wold WS, Lichtenstein DL. 2009. INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies. Cancer Gene Ther 16:625-637. https://doi.org/10.1038/cgt.2009.6.